Last reviewed · How we verify
B. CNS 7056
B. CNS 7056 is an investigational drug with a mechanism that is not fully disclosed publicly.
At a glance
| Generic name | B. CNS 7056 |
|---|---|
| Also known as | CAS No. 1001415-66-2, Remimazolam |
| Sponsor | Paion UK Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The specific action of B. CNS 7056 at the molecular level is not detailed in public sources, making it difficult to provide a precise mechanism of action.
Approved indications
Common side effects
Key clinical trials
- REMIMID-ICU: Remimazolam vs Midazolam for Deep Sedation in Hemodynamically Unstable, Mechanically Ventilated Adults (PHASE3)
- Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia (EARLY_PHASE1)
- Remifentanil and Remimazolam to Limit Patient Movement (NA)
- 95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment (NA)
- The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg (NA)
- A Trial of Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation (PHASE2)
- Remimazolam Reduces Emergence Delirium in Preschool Children Undergoing Laparoscopic Surgery by Sevoflurane Anesthesia (PHASE4)
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B. CNS 7056 CI brief — competitive landscape report
- B. CNS 7056 updates RSS · CI watch RSS
- Paion UK Ltd. portfolio CI